Skip to main content

NanoString, Mayo Clinic to Develop Novel Assays in High-Risk Breast Cancer and Leukemia

NEW YORK – NanoString Technologies and Mayo Clinic Laboratories said today that they will collaborate to develop clinical tests using NanoString's GeoMx Digital Spatial Profiler and nCounter technologies.

Under the agreement, the two organizations will embark on a cross-site study applying the GeoMx DSP technology to investigate the immune architecture of high-risk hormone receptor positive HER2-negative breast tumor samples.

GeoMx combines spatial and molecular profiling technologies, generating whole-tissue images at single-cell resolution and allowing digital profiling of tens to thousands of analytes in up to 16 to 20 tissue slides per day. Using the platform, the partners aim to elucidate biological mechanisms that drive aggressive breast tumors, which could lead to the development of new prognostic or predictive biomarkers. 

A second study under the collaboration will evaluate the use of NanoString's nCounter fusion assays as a scalable and cost-effective alternative to conventional FISH testing in leukemia.

Financial terms of the agreement were not disclosed.